STOCK PURCHASE AGREEMENTStock Purchase Agreement • September 16th, 2024 • Avalon Ventures XI, L.P. • Pharmaceutical preparations • Delaware
This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of September 12, 2024 (the “Effective Date”), by and among RA Capital Healthcare Fund, L.P., a Delaware limited partnership (the “Purchaser”), on the one hand, and Avalon Ventures XI, L.P., a Delaware limited partnership (“Avalon XI”), Avalon BioVentures I, LP, a Delaware limited partnership (“ABV I”), and Avalon BioVentures SPV I, L.P., a Delaware limited partnership (“ABV SPV” and together with Avalon XI and ABV I, the “Sellers” and each a “Seller”), on the other hand.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • March 4th, 2024 • Avalon Ventures XI, L.P. • Pharmaceutical preparations
The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Janux Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • June 5th, 2024 • Avalon Ventures XI, L.P. • Pharmaceutical preparations
The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Janux Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
EXHIBIT C JOINT FILING AGREEMENTJoint Filing Agreement • June 25th, 2021 • Avalon Ventures XI, L.P. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Janux Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
EXHIBIT B FORM OF LOCK-UP AGREEMENTAvalon Ventures XI, L.P. • June 25th, 2021 • Pharmaceutical preparations • New York
EXHIBIT A JOINT FILING AGREEMENTJoint Filing Agreement • September 16th, 2024 • Avalon Ventures XI, L.P. • Pharmaceutical preparations
The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Janux Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
EXHIBIT C JOINT FILING AGREEMENTJoint Filing Agreement • November 16th, 2023 • Avalon Ventures XI, L.P. • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Janux Therapeutics, Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.
